Soluble PD-1 (sPD-1) therapy involves administering recombinant sPD-1 to bind both membrane-bound and soluble PD-L1, preventing interactions with PD-1 on T cells and restoring anti-tumor immunity. Here, HOXD13 is linked to neoplasm.